

Cynomolgus FGFR2(IIIb) D1-D3 Protein; His Tag

Product Information


Product Name	Cynomolgus FGFR2(IIIb) D1-D3 Protein; His Tag
Storage temp	Store at $\leq -70^{\circ}\text{C}$, stable for 6 months after receipt. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Catalog# / Size	GM-88190RP-100 / 100 μg GM-88190RP-1000 / 1 mg

Protein Information

Alternative Names	FGFR2B, FGFR2
Source	Cynomolgus FGFR2(IIIb) D1-D3 Protein; His Tag (GM-88190RP) is expressed from human 293 cells (HEK-293). It contains AA Arg 22 - Glu 378 (Accession # A0A2K5TL84-1). This protein carries a His tag at the C-terminus.
Purity	> 95% as determined by SDS-PAGE
Endotoxin	< 1 EU/ μg , determined by LAL gel clotting assay
Predicted Mol Mass	40.4 KDa
Formulation	Supplied as a 0.2 μm filtered solution of PBS, pH7.2-7.4.
Description	<p>FGFR2 (Fibroblast Growth Factor Receptor 2) is a transmembrane receptor tyrosine kinase that belongs to the FGFR receptor family. By binding to its ligand fibroblast growth factor (FGF), it activates intracellular signaling pathways such as RAS-RAF-MAPK, PI3K-AKT, and PLCγ, thereby regulating cellular processes including proliferation, differentiation, migration, and survival. FGFR2 has typical structural features: an extracellular three-layer immunoglobulin-like (IgG-like) domain, a transmembrane region, and an intracellular kinase domain. Different exon combinations (such as splice variants IIIb and IIIc) determine its tissue expression patterns and binding specificities.</p> <p>Aberrations in FGFR2, especially in various solid tumors, are closely associated with disease. Genomic alterations such as point mutations, amplifications, and fusions can lead to constitutive activation of signaling pathways, promoting tumor growth and invasion, making FGFR2 an important target for therapy. Multiple FGFR2 inhibitors (including small-molecule inhibitors and antibody-drug conjugates) have shown potential in clinical research and treatment, with some drugs approved for specific tumor types or entering clinical trials.</p>

Version:4.0

SDS-PAGE




On SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Bioactivity-ELISA

Bioactivity-ELISA

0.2 μ g Cynomolgus FGFR2(IIIb) D1-D3 Protein; His Tag of per well



Cynomolgus FGFR2(IIIb) D1-D3 Protein; His Tag (Catalog # GM-88190RP) was immobilized at 2 μ g/ml (100 μ L/well). Increasing concentrations of Anti-FGFR2 hIgG1 Reference Antibody (Bemabio) (Catalog # GM-88057MAB) were added.